Bevacizumab Use in Preemies Associated With Disabilities

Share this content:
Bevacizumab Use in Preemies Associated With Disabilities
Bevacizumab Use in Preemies Associated With Disabilities

FRIDAY, March 18, 2016 (HealthDay News) -- Bevacizumab (Avastin) used to treat retinopathy of prematurity (ROP) may be linked to serious disabilities such as cerebral palsy and hearing loss, according to a study published online March 17 in Pediatrics.

Julie Morin, M.D., of the Sainte-Justine University Hospital Center in Montreal, and colleagues looked at 27 infants whose ROP was treated with bevacizumab, and 98 treated with laser surgery.

The researchers found that the odds of severe neurodevelopmental disabilities were 3.1 times higher in infants treated with bevacizumab versus laser, after adjustment for gestational age, gender, maternal education, Score for Neonatal Acute Physiology-II, bronchopulmonary dysplasia, sepsis, and severe brain injury.

"Preterm infants treated with bevacizumab versus laser had higher odds of severe neurodevelopmental disabilities," the authors conclude. "Further investigation on the long-term safety of antivascular endothelial growth factor treatment of ROP is needed."

Avastin manufacturer Genentech could not be reached for comment.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »